M
Metagen Therapeutics
Biotech & Life Sciences · Tsuruoka-Shi, Japan · Founded 2020
Microbiome-based therapeutics for various intractable diseases. MoreLess
Metagen Therapeutics (MGTx) is a clinical-stage company operating Japan’s first GMP-compliant manufacturing platform for fecal microbiota transplantation (FMT) therapies. The company combines proprietary paired metagenomic datasets with AI/ML-driven donor-recipient matching to advance precision microbiome medicine across ulcerative colitis, immuno-oncology, and neurodegenerative disease.
Headquartered in Tsuruoka, Japan, MGTx leverages a cross-border regulatory strategy spanning PMDA and FDA pathways, positioning it as a platform bridging Japanese clinical innovation with global market access.
Talent graph
Metagen Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
16 investors on Metagen Therapeutics's cap table
Sourced from Dealroom's funding history.
Global footprint
Where Metagen Therapeutics has talent and traffic
team presence
Market sentiment
What the market is saying about Metagen Therapeutics
An AI-synthesized read of the highest-engagement posts about Metagen Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Metagen Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.